Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | STAT6 | P42226 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23340495 | 0.85 | DRD2 (0.32) | NUDT5LMNASTAT6SMN1; SMN2 | |
| SCHEMBL23340704 | 0.79 | NUDT5 (0.56) | NUDT5HTR2CDPP4L3MBTL1POLB | |
| SCHEMBL23297577 | 0.78 | NUDT5 (0.73) | NUDT5DPP4L3MBTL1LMNASTAT6 | |
| SCHEMBL23340325 | 0.78 | NUDT5 (0.54) | NUDT5HTR2CLMNAPTPN11 | |
| SCHEMBL23340460 | 0.77 | POLB (0.39) | NUDT5HTR2CDPP4SMN1; SMN2POLB | |
| SCHEMBL23340617 | 0.77 | NUDT5 (0.52) | NUDT5LMNASTAT6SMN1; SMN2 | |
| SCHEMBL23340491 | 0.74 | HTR2C (0.43) | NUDT5HTR2CDPP4L3MBTL1LMNA | |
| SCHEMBL23340639 | 0.73 | NUDT5 (0.47) | NUDT5HTR2CLMNASMN1; SMN2POLB | |
| SCHEMBL23340553 | 0.72 | NUDT5 (0.47) | NUDT5HTR2CDPP4LMNASMN1; SMN2 | |
| SCHEMBL23340497 | 0.72 | NUDT5 (0.47) | NUDT5HTR2CDPP4LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128566-A1 | NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128566-A1 | NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE | ADORA2A, HPRT1, PNP | NUDT5 105/4885HTR2C 1202/4885DPP4 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.